Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLRK1 | P26718 | 6/20 | 0.43 |
| ▸ | MICA | Q29983 | 6/20 | 0.43 |
| ▸ | RAET1L | Q5VY80 | 6/20 | 0.43 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23384954 | 0.90 | KLRK1 (0.39) | KLRK1MICARAET1LCTSKCTSS | |
| SCHEMBL29826428 | 0.90 | KLRK1 (0.39) | KLRK1MICARAET1LCTSKCTSS | |
| SCHEMBL3218001 | 0.86 | CTSS (0.45) | KLRK1MICARAET1LCTSKCTSS | |
| SCHEMBL1115223 | 0.84 | CTSS (0.45) | CTSKCTSSS1PR3TRPA1GABRB1 | |
| SCHEMBL12847456 | 0.83 | CTSS (0.41) | CTSKCTSSS1PR3TRPA1GABRB1 | |
| SCHEMBL1115072 | 0.83 | CTSS (0.41) | CTSKCTSSS1PR3TRPA1GABRB1 | |
| SCHEMBL8351861 | 0.80 | CTSK (0.60) | KLRK1MICARAET1LCTSKCTSS | |
| SCHEMBL8235992 | 0.78 | KLRK1 (0.59) | KLRK1MICARAET1LCTSKCTSS | |
| SCHEMBL17041589 | 0.78 | KMT2A (0.43) | CTSKCTSSTRPA1GABRB1GABRB2 | |
| SCHEMBL12791268 | 0.78 | KMT2A (0.43) | CTSKCTSSTRPA1GABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| EP-4059928-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021093795-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉朗来科技发展有限公司 | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | KLRK1 4820/4885MICA 3992/4885RAET1L 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.